bluebird bio, Inc. (BLUE) Director James Mandell Sells 1,000 Shares
bluebird bio, Inc. (NASDAQ:BLUE) Director James Mandell sold 1,000 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $95.95, for a total transaction of $95,950.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $95,950. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
bluebird bio, Inc. (BLUE) traded up 0.47% during mid-day trading on Tuesday, reaching $97.05. 313,313 shares of the company were exchanged. The company’s market capitalization is $4.42 billion. bluebird bio, Inc. has a one year low of $37.05 and a one year high of $123.75. The stock has a 50-day moving average price of $98.08 and a 200 day moving average price of $90.65.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. bluebird bio’s revenue was up 977.4% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.59) EPS. Analysts predict that bluebird bio, Inc. will post ($6.78) EPS for the current year.
Several large investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in bluebird bio during the first quarter valued at approximately $858,000. Winfield Associates Inc. raised its stake in bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the last quarter. Macquarie Group Ltd. acquired a new stake in bluebird bio during the fourth quarter valued at approximately $703,000. Finally, Alliancebernstein L.P. raised its stake in bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock valued at $7,805,000 after buying an additional 28,640 shares during the last quarter.
A number of research analysts have weighed in on the stock. Cantor Fitzgerald set a $39.00 price objective on shares of bluebird bio and gave the company a “sell” rating in a research note on Saturday, June 24th. Jefferies Group LLC reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, July 6th. Sanford C. Bernstein assumed coverage on shares of bluebird bio in a research note on Thursday, July 27th. They issued a “market perform” rating and a $109.00 price objective on the stock. BMO Capital Markets reaffirmed a “buy” rating and issued a $108.00 price objective on shares of bluebird bio in a research note on Friday, August 4th. Finally, Morgan Stanley reaffirmed a “hold” rating on shares of bluebird bio in a research note on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company’s stock. bluebird bio has an average rating of “Hold” and an average target price of $100.66.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.